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Hemodynnmics and myocardial meiakohsm at rest and during 
exereiw were investigaied in 21 patients with heart hilure. The 
paliiats were ~valoaled before and zlker long+xm treatment 
(14 1 7 months1 with the beta-adrenergic blocking agem 
netaprolol. Clinical improvemrnc with incrcasrd functional 
enpncily occurred during treatment. hloximal work load in- 
crawl by 25% (1Od to 130 W; p < 0.001). Hemadynamic dsla 
showed an increased cardiac index (3.8 to 46 liledmin per m’; 
p < 0.02) during exercise. Pulmonary capillary wedge pres. 
sure decreased at resl (20 to 13 mm Hg: p < 0.01) and during 
exercise (32 b 28 mm Hg; p = NS). Slroke volume index UO to 
39 tq~~‘n-~; p < 0.006) and stroke work index (26 lo 46 am/m’: 
p < 0.00606) ineremed during exercise and lonp;(erm meluprolol 
IreatnlenL 
The mlerial nnrepinephrine caneentralion decrewd at rest 
Unloading of rhe failing hean has been rhe mosx successful 
principle of treatment in congcslivc heart failure. Vasodila~ 
tar drugs ‘we been used to reduce augmented preload and 
afterload. Disturbances in neurohormonal sysrems. such as 
activation. of the renin-angiotensin-aldosterone system. arc 
well known (II and treatment with angiotensin-converting 
enzyme inhibitors has been very successful I?). To improve 
reduced myocardial contractility. several inoiropic drug% 
have been clinically tested to increase adrenergic stimulalion 
or inhibit cyclic adenosine monophasphatc breakdown. 
However. an activated symparhetic nervoo~ system is an- 
other characteristic of congestive heart failure and. nllhough 
short-term beneficial results have been achieved with ino- 
tropic drugs (3.4). long-term trials (5-7) have no1 been 
successful. 
The concepl of protecting the hiling heart by reducing 
adrenergic overstimulation with a beta-adrenergic blocking 
agent Has described I7 years ago I81 but has only recently 
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13.72 tu 2.19 nmoL?iBr; p < 0.02) but not during exercise f 13.2 lo 
II.1 nmolili~rr: p = NS). The art&I-comw sinus norepinepb- 
rine diCCerence suggesled a decrwe in mwcardial spiltover during 
mempmlol wealmenf !-0.2fi to -0.13 nmnlili~cr; p = NS at IX! 
and -1.13 to -0.27 omollliler; p < 0.05 during erercirel. 
Coronary sinus blond Aow was unchanged during treatmel. Four 
pafientr pmduced myncardiil lactate before the study. but none 
produced lactate afler betabfmkade (p < 0.0% There was no 
obviaas imprownenl in a sutqroroup of patients with ischemic 
cardiam!opaihy. 
In swnmary. there were rignns or iwrea%d myocardiai work 
load without higher melakolic costs alter treatment with meto- 
prulol. 
(J Am Cd Cordial 1991;18:1059-66) 
- 
gamed widespread arceprance. WaagTtein el al. (8) were rhe 
5: ! tn rrpcr! clinica! improvement after shofl-term admin- 
islration of a bcta-blocker in patients with congestive heart 
fmlurc due 10 recent myocardial infarction. Although subse- 
quent short-term stud::\ oy other invesliga;lrors (9.10) were 
unable to reproduce I me findings. more recent long-term 
~nals (I I.121 have shown the beneficial effects of bna- 
blockade. The precise mechamsm for Ihe improvement is 
still poorly undenrood. tong-term beta-blockade tends IO 
normalize beta-receptor function. which is down-regulated 
in congcstivc heart failure. The myocardial response may 
thus be increased when the heart is subjected lo inolropic 
slimulallan (131. Beta-blockade results in a decreased heart 
rate. which leads IO improved diastolic function 114.15). 
improved myocardial pelfusion and reduced myccardial 
oxygen conwmptmn (Ih). 
Tlw prirrwv objrcrivr of rhb srady was 10 dewmine 
whether the favorable effects on myocardial performance 
and metabolism achieved a1 rest would be maintained during 
exercise in pauents with severe heart failure healed with 
long-term beta-blockade. A secondary objcclive was to 
study the effects on circulating catecholamines as an index 
of disease severity. Most previous beta-blockade studies 
have been performed in patienls with dilated cardiomyopa- 
thy. In this wdy. ir was Intended to evaluate the elfecls 
of bela-blockade in patients wth heart failure of varied 
oripm 
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Study patients (Table 1). From 1984 to 1987. 21 palients 
(19 men and 2 women; mean age 51 years [range 24 to 671) 
with ce~ere heart failure were included in the study. Heart 
failure was secondary to idiopathic dilated cardiomyopathy 
in I.1 patients, ischemic cardiomyopathy in 6, status after 
valve replacement in I patient and rheumatic cardiomyopa- 
thy in I. All patients with severe heart failure resembling 
dilated cardiomyopathy were considered for the study. Dur- 
ing the study period. 40 patients at our institution met these 
criteria. Because ofthe extensive study protocol, I5 patients 
were followed up with a simpler invasive protocol. Four 
patients did nut tolerate the lest dose of metoprolol. These 
patients have been described previously (II), togclher with 
the patients with idiopathic dilated cardiomyopathy from the 
study period who are not presented in this report. The 
patients were receiving standard therapy but still had limited 
functional capacity. 
Left ventricular function was diffusely impaired in all 
patients with ischemic cardiomyopathy and no patient had 
symptoms of anginal chest pain. Four of the six patients with 
ischemie heart disease had significant coronary artcry ob- 
struction on coronary angiography. In two patients. the 
diagnosis of coronary heart disease was discbsed after the 
study period (one at autopsy and one after heart tzmsplatt- 
tatian). Three patients had a history of myacardial infarction 
and one palient had a history of angina peclorir. Coronary 
angiography in the patients tvith dilated cardiomyopathy, 
valvular heart disease and rheumatic cardiomyopathy 
showed no significant coronary artery obstruction. 
No patient had a history of excessive alcohol eonsump 
tion. Myocardial biopsy specimens obtained from the pa- 
tients with idiopathic dilated cardiomyopathy and rheumatic 
cardiomyopathy showed no signs of utyocarditis or other 
specific heart disease. The patient with rheumatic cardiomy- 
opathy presented with heart failure and clinical findings of 
dilated cardiomyopathy. She developed serologic and clini- 
cal signs of rheumatoid arthritis after the study period, at 
which time her cardiac symptoms had improved. There was 
no sign of rheumatic valvular disease. The patient with 
valvular heart disease had had sonic valve rep!acentcn~ 
I3 years before the snrdy. Signs of heart failure developed 
3 years later. The mi!ral xdve was replaced with a biologic 
prosthesis 5 years before the study. At the time of the study. 
echocardiography showed no signs of valvular dysfunction, 
Metoprolol treatment. Before long-term treatment, the 
patients received a test dose of the selective beta,-blocker 
mctoprolol (5 rng twice daily for 2 days). No patient had a 
deterioration in physical status or showed increased signs of 
heart fadure or hypolen6nn. Treatmen! vr;l~ commucd wth 
slowly increasing doses according to the Adlowing zchedu!e, 
days I 10 3. 5 mg twice daily; days 4 to 7. 5 mg three timer 
daily; days 8 to II. IO mg twice daily: days I! to 14. 10 mg 
three times daily: days 15 to 18. 25 mg twice daily: days IY 
to 21. 25 mg three times daily: days 2: to 3. 50 mg tstce 
daily and day 26. 50 mg three times daily A fimd mean dose 
of 127 mg (range 75 to 2001 was achiever!. 
The final dosage was determined by rhe c!inical status of 
the patient and with consideration of adverse effects. of 
which fatigue and hypotension were rv ~OSI common. 
There was no change in concomitant tremment. except for 
adjustment of diuretic drugs. Cardiac wtheterization was 
performed before and after 6 to I2 months of freatmen~ wih 
metoprolol. If obvious additional clinica’ improvemem oc- 
curred after !he second study. a new study was performed. 
Thus, six patients had data from a third catheterization. 
which were used in this analysis. The mean ~reaunem pewd 
ws 14 months (range 6 IO 30). 
imesfigutions 
Pmhml. Day I. The patient was examined aith twc’o- 
dimensional echocardiography or radionuclide angiocardiog- 
raphy. A maximal sitting bicycle excrci)c test starting ar 
20 W with increments of IO Wlmin was performed. 
D&y 2. Right heart catheterization was performed in the 
morning with the patient in a fasting shk without prcmcdi- 
cation. All medications were co&wed during the investiga- 
tions. A triple-lumen Swan-Ganz pulmonary artery catheler 
and a Wilton-Webster coronary sinus catheter were intm. 
duced percutw~eously through the internal jugular wn. The 
correct position of the coronary sinus catheter was checked 
by Buoroscopic injection of radiopaque medium and by 
tracings offlo-#curves. An arterial line uasobtaincd through 
the radial artery. Pressures. flows and blood samples were 
obtained at rest. The patients then performed supine bicycle 
exercise at a fixed load of 50% of their maximal work load as 
determined from the exercise test performed the previous 
day. After 4 min of exercise. pressures were recorded and 
thereafter flow measurements and blood sampling were 
performed during continuous exercise. 
Measurements. Left ventricular ejection frae~ion wa\ cal- 
culated fmm M-mode echocardiognphic recordings. Ade- 
quate M-mode tracings were obtained in all but tao patients. 
During the study period radlonuclide anglography was mtro- 
duced at our inslirution, and the last 6x patw~ts emo!!cd :z 
the st-dy (ii;cli;dii;g :h:ee cf !he six patients with ischemic 
cardiomyopathy) also underwent equilibrium radmnuciide 
angiography. L : ventricular ejectiun frachon was esli- 
mated from time-activity curves and was used in the analysic 
if these data were available. Functional wtus was assessed 
according to the New York Heart A~~oc~auon funcuonal 
classiiicmion in an unblinded fashion. All patients were 
evaluated by at leabt 1v+o independent cardi+&.. Pres- 
Fg = F, x k(K - ,). 
where F, = infusion rate; T,. T,. T,, = tempermure of 
blood. mjcctatc u~d mixture of blood and inje&ttc. rcrpec- 
tively: and k * a consmnl derived from the density and 
wx!fic heat of saline solution and blood. Biaod samples 
were obtained for analysis of ouygeen content dnd catcchol- 
amine ard lactate concentrations. Norepinephrine and epi- 
ncphrinc levels in pbma were mca,ured by using high 
performance liquid chromatography with electrochemical 
detectiun as described previously (19). Lactate was analyzed 
with an ew matic melhod (Lactate Analyzer 640. Rache 
Blo-EleCrr*lllL\I. 
Duid wioblrs. The fottowing calculations were pcr- 
formed: Cardiac mdcx = Cardiac output/Body surface arca; 
Stroke votume mdcx = Stroke volume/Body surface area: 
Slroke work index = IMean artery pressure - Pulmonary 
capillary wdgc prebruret x Stroke volume index x 0.0136; 
Oxygen conramp.~~n index = Cardiac index x Arteriove- 
nou o‘;ygcn &fference: Rate-pressure product x Mean 
arterial pressure x Heart rate: Systemic YBSCUIX resistance 
= &lean anerlal pressure - Right atrial pressurel/Cardiac 
m~lpul: Myocardial oxygen consumption = Coronary Ficus 
Ruw x IArlerial oxygen content Coronary sinus oxygen 
co”telX,. 
ln four pil&nts. the pulmonary capillary wedge pressure 
tracings wre of poorquality dur’ng exercise and pulmonary 
dmslolic pressure was therefore subsmuted for pulmonary 
capillary wedge pressure. In these padent% thcrc was good 
agreement between pulmoaary capillary wedge pressure and 
pulmonary diasIolic pressure at re~1. Coronary sinus flow 
rracings could nol be obtained in all patients because of 
difficulties in positioning or dislodgment of the catheter 
durmg exercise. 
Statistical melhods. Student’s paired f test was used to 
compare differences in hemodynamt values before and after 
trearmenr. Measurements of myocardial metabolism con- 
tained fewer dam and nonnormal distribution was aszumed. 
The Mann-V!L(:ney nonparametric test was used for 31ter- 
grczp comparisons. All values are expressed as mean values 
t I SD unless otherwise stared. 
The study has approved by the Ethics Committee of the 
Medical Faculty. University of Gbteborp on April I. IYSI. 
Particlpming pmients gave informed consent before inclu- 
hion m the study. 
Results 
Functional and norking capacity. Mean functional capac- 
ity. expressed as New York Heart Acwcintinn func!ionnl 
class. mcreased during long-term melopralol therapy (from 
3 IO 2.3: p < 0 WI). Maximal workingcapoci~y increased by 
25% Ifrum 104 i 40 to 130 I 41 w; p e 0.0(111. Bcoauas tt,r 
supine work load u,as derived from the maximal sitting work 
load. on averace. the patient w’farmcd hewer work at the 
rrcond mveat&mn i48 ? 20’~s. 60 t 24 W. respectivrlyl. 
LcR ventricular ejection fractton increased from 21 * 7% to 
32 * 12% (p c O.tMll. 
Hemodynsmic data (Table :I. With luns_term metoprolol 
Ihcmpy. pulmnnary capillary wcdgc prcsrure decrcarcd tp < 
U.UI I al rrst bul nut significantly durinc exercise. There wn< 
rate decreased at rest but showd no ugnitiant chap 
during exercie. The systolic and mean artertal prewres 
increased in the rest state. Duringexercise, the mean arterial 
pressure increased by 13%. The rate~prerrure product wns 
not changed by beta-blockade, whetsah rtruke work index 
increased by 64% during exercise and to a corresponding 
extent I rest. There were no significam alrerarions in 
pulmonary and systemic vascular resistance during treat- 
ment. Individual data during exercise for the p&x$ with 
nonischemic (n = 121 and ischemic (n = 61 disease are shown 
in Figure I htroke work index) and Figure 2 (cardiac index). 
The subgroups were too small to allow for statistical infer- 
ence. 
Mpxardial metabolism (Table 3). Corcaxy sinus Row 
increased during exercise. but then was no chaqe with 
metoprolol treatment during either rest or wk. Likewise. 
myocardial ohygcn consumptian was unaltered by me- 
protol. although katues were higher during exercise. At 
baseline study. &?ur palents produced mrocardial lacrarc PI 
rest and IWO produced Lactate during exercie After Bela- 
blocker ~restment. there uwc ,,a lactate producers ,p < 
BASELIIUE METOPROLC 
Figure 2. Cardiac Index dunng exercix 
sludv and wlh lonklerm hsla-blacker 
oi-A 
BASELINE METOPSOLGL 
0.05). Lacmte concentratwn difference belwen xwrial 
and coronary sinus blood was increased [rum an avrrqc 
O&4 mmollliter prnducrion at baseline wdy to rm ewac- 
lion of 0.179 mmolkr with meroprolol lp < O.W!. Durmg 
exercise. Ihe levels were 0.609 and 0.913 mmol!lilcr. re>pcc- 
lively (p < 0.17) (Fig. 3). 
Catechalamines (Table 3). Artenal norepmephrme levels 
decreased by 41% (from 3.72 to 2.11) nmnlJlirer1. The levels 
during exercise were substantially higher than a~ rert and 
values obtained during metoprolol therapy did not differ 
from those at baseline sudy. Coronary rinus levels of 
norepinephrine were lower at rtx~ than during cxerc~se and 
comparable with arterial levels. The arterial-coronary iinuz 
norepinephrine concentralion difference ~horced a tendency 
toward less spillover on long-term metoprolol therapy [Fig. 
4). The arterial levels of epioephrire wrc higher dorm: 
Table 3. ,Mvocardlal M&abolic Data From 19 Pallent\ 
BASELINE METOPROLOL 
Effects of long-term metoprolol therapy. P;.tlenrs re- 
spond~d fworably 10 long-term beu-blockade m demon- 
wared by increased working capacity. and rhz mcrement 
we’d\ cnmparahle with that achieved by anglotensin- 
convening enzyme inhibirors (X21). Moreover, cardiac 
ootpm and tilling prcsswcs lmprovcd at rcs~. Aficr hcta- 
blocker twllrncxt. there was an ~~~crcase in arterial pressure. 
cardiac oo~~ot and stroke work during cxcrcise. whcrtxs 
hew Me and filling pressures were unchanged. There were 
signs of rcduccd myocardial ischemia as judged from the 
reduced number of lacla~e producers. Norepinephrine blood oulpu~ increased and heart rate was unchanged during 
level> decreased during treatmenl. exercise. 
Methods. In thi5 study. we derived the supine exercise These findings imply different cardiovascular eflects of 
work load from the maximal work load inwad of wing the beta-blockade in the failing heart as compared with the 
same supine work load at both inverligalions. Two-level normal heart and the hean with hypertension and angina 
exercise was loot appropriate at the second investigation. pectoris. One interprelation may be that long-term adminis- 
because the natienls could not have endured B lancer oetiod w&on of metoorolol induces an uo-rwulalion of beta- 
of supine ex&cise. A wing exercise lest would hav; been rece#ors. per&ing improved chron&ro$c and inotropic 
preferable physiologically bul the supine exercise model :vas responses during exercise (13). The lower heart rale induced 
chosen because I, allowed for control of three catnetcrh and by beta-blockade could favor hemodynamic adaptation with 
numerous measuremenls. Meacuring myacardial blood Row improved myocardial pafusion and ventricular filling during 
by using the thermodilurion technique. as in the present diastole, supporting myocardial recovery and possibly ex- 
study. is subject lo substantial melhodologic variability plaining the improved comracIilLy. In contrast to classic 
when applied on different occasions. However, no other vasodilators 127) and beta-blockers with vasodilator proper- 
method swable both al rat and during subseauent exercise ties (28.29). long-term metovrolol lreatment caused only 
in the same invesligallon ib available for long&m studies. 
Hemodynamics. Several findings in lhls study implied 
improved myocardial contractility aflcr long-term treatment 
wlih metoprolal. De5pile hem-blockade. the exercise heart 
rate reached the same level as before treatmen,. The reduced 
chronotroplc response found in conge>live heart failure 122) 
thus Ieemed to be partially restored. This result is in 
accordance wth the findings of Heilbrunn et al. 113) durmg 
long-term be&blockade with dobutamine slimulalion. There 
are equivocal result, concerning the effect of beta-sdrenergic 
receptor blockade on exercise tolerance and maximal oxv- 
minor changes in peripherai vascular resistance and the 
improvement is therefore not likely 10 be secondary lo 
vasodilalion. Moat ofthe patients were already being treated 
with an angiotensin-convening enzyme inhibitor when they 
entered this study. implying that beta-blockade has ao addi- 
tional favorable elfect in chronic heart failure. 
Catecholamines. The present study is the first 10 demon- 
strate decreased arterial levels of norepinephrine in response 
to long-term beta-blockade in patients with hcarl failure. 
This finding is in agreement with the observed clinical and 
hemodvnamic immovement of the oatients. There me at 
gen consumption under other conditions (23.24). In he&y least fdur possiblf explanations for the reduced norepineph- 
subjects wrated with a beta-blocker. woke volume in- rine levels. I) The &we&lion of betweceptors would 
creases. cardiac output is maintained and systolic blood decreae the need for sympathetic slimulation. 2) The 
prcrsure and heart rate decrease during cxcrcise (25.26). In effecr could be mediated by the adrenergic receplors in the 
ihis study, stroke volume, arterial pressure and cardiac central nervous system 130-32). Reduced sympathetic acliv- 
iiy has been reported (33) after treatmi.u &lth Ihe hpld- 
soluble beta-blocker mr~oprolol. wherea\ the water-soluble 
compound atenolol increased plasma noreptnephrine coil. 
centrations (&lad. personal commumcat~oa: 341. 31 Long- 
term beta-blockade may block presynaptic beta-receptors 
and thus reduce uewous system-iwIosed norepinephtine 
overflow 135). 41 The lower levels of plasma norepinephrme 
could be secondary IO improved myocardial function. Sur- 
gical uttervention 136.371 or medtcal trealmem (38.39) have 
both resulted in decreased levels pwallcl to symptomatic 
improvement. 
Myocardial metabolism. It has been found that bera- 
blockade reduces myocardial oxygen demand t40.411 and 
increases myocardtal lactate e~tracl~on (42.43) in angma 
pectotis. Reduced total coronary blood flo\c t40.41) and 
increased subendocardial blood Aoo 144.451 have been ob- 
served. In this study, we also found a reductton in the 
number of lactate producers and no change in myocardial 
oxygen consumption and total coronary sinus tIow &:r 
metoprolol treatment. Arterial lactate levels tended to be 
higher during exercise after beta-blocker treatment. \rhich 
may suggest that the patients managed to perform greater 
muscle activitv after treatment (461. 
Elfology of heart failure. Is the r&onss to beta-blockade 
smtilar in heart failure cl dtffereni causes? Although this 
question could not be answered by this study. our data 
suggest that patients with nonischemtc myocardial involve- 
ment have a better chance of benefiting from beta-blockade 
than do uatients with coronary arterv disease. Some of the 
patients’with nonischemic c&fiom~*opathy exhibited re. 
markable clinical improvement. !n the group with ischemic 
cardiomyopathy. there was no obvious improvement. Nev- 
ertheless. there wnre no evident signs of deterioration during 
long-lsrm follow-up atwly. This apparent stabili@on could 
possibly be a positive sign in a patient group with an 
otherwise foor prognosis. These patients have more exten- 
sive fibrosis and are therefore less likely to increase the total 
amount of functioning myocardium. fn recent reports 
(13,471, it was suggested that the positive effect of bet+ 
blockade was correlated with the degree of fibrosis. None of 
these patients underwent coronary revasculariration. Such 
operations before beta-blockade might have yielded different 
rc~uhs. Beta-blockade may have a prevemive effect on an 
ongoing fibrosis by decreasing ischemia. especially in subcn- 
docardial layers (44). 
Tolerance. Some patients with congestive heart failure 
do not tolerate beta-blockade. II is our impresston that 
patients with very severe heart failure and extensive myo- 
cardial damage reprehem a group ahore condition does not 
improve with long-term beta-block&. These patients may 
not have enough viabte myocardium. and therefore blockade 
of the few remaining beta-receptor% would lead to inotropic 
failure. It has been suggested (17) that au elerated right atrial 
pressure and a very low ejection fraction arc prognostic 
signs for intolcrancc to beta-blockade. Ncverthele\s, even 
\ome patients with lale stage 111 or IV heart iai!ure do 
respond well to long-term treatment with metoprulol. 
LimitationsoFlhesiudp. This was an open stud) and thus 
subject to the inherent veaknerces of such a trial. The open 
study design was used because it war the first time beta- 
blocker theraoy was asscrsed in a group of psttents wth 
heart failure 3f different causes. The patients served as their 
own controis. Some patwus had very slow improvement 
and Ihe extension of tht treatment period to Pb months 
made il do&c blind study ddliculr. A similar siudy in 
patient> with c&ted cardiomyopathy with a randomized 
placcho-conrrc led design was started in 1986 and is now in 
pr*gres5 
Conclusion. Long-term beta-blocker treatment in pa- 
tients with heart failure improved working capacity, tilling 
pressures and cardiac output. Ctrculating arterial norepi- 
nephrine !evels decreased and myocardial energerics im- 
prored allowing increased myocardial work lcod without 
higher metabolic costs. 
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